Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $120 to $134.
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $120 to $134.